Holen Sie sich die Stockscreener-App
0.7051
2.33%
-0.0168
Handel nachbörslich:
.71
0.0049
+0.69%
Estrella Immunopharma Inc Aktie (ESLA) Neueste Nachrichten
Estrella Immunopharma Receives Nasdaq Minimum Bid Price Notice - TipRanks
Estrella Immunopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
ARMISTICE CAPITAL, LLC Reduces Stake in Estrella Immunopharma Inc (ESLA) by Nearly Half - GuruFocus
Estrella Immunopharma Inc. (NASDAQ: ESLA) Share Price, ESLA Stock News, ESLA Share Price & Updates - Kalkine
Estrella Immunopharma (ESLA) Holds Ground at $0.72 as Immunotherapy Pipeline Takes Center StageLong Short Pair - vinanet.vn
Price to earnings forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Estrella Immunopharma (ESLA) Holds at $0.72 as Support Firms in Quiet Micro-Cap SessionIchimoku TK Cross - vinanet.vn
ESLAW Warrants Hold Flat at $0.07 as Support and Resistance AlignInstitutional Buy Signals - vinanet.vn
ESLAW Warrant Holds at $0.07 as Estrella Immunopharma Trades FlatSystematic Flow - vinanet.vn
Estrella Immunopharma (ESLA): Armistice Capital discloses 4.99% ownership stake - Stock Titan
Estrella Immunopharma, Inc. 2Q 2026: Net loss $(2.31M), EPS $(0.05) — 10-Q Summary - TradingView
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - BioSpace
Estrella adds fourth site to EB103 lymphoma trial - Investing.com
Estrella Immunopharma Inc (ESLA) Stock News Today - TradingKey
Estrella Immunopharma (ESLA) Stock Price, News & Analysis - MarketBeat
Estrella Immunopharma Inc (ESLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Estrella Immunopharma (ESLA) Rallies 6.11% as CAR T-Cell Focus Draws Investor AttentionTotal Put Call - dars.gov.et
Price to book forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - tradingview.com
Estrella adds third site to EB103 lymphoma trial - Investing.com
Estrella adds third site to EB103 lymphoma trial By Investing.com - Investing.com South Africa
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - Yahoo Finance
Estrella Immunopharma (ESLA) Holds at $0.71 as Downside Pressures Remain ContainedTRIN Signal - dars.gov.et
Price to sales forward of Estrella Immunopharma, Inc. – BOATS:ESLAW - TradingView
Price to book forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Estrella activates second site for EB103 lymphoma trial By Investing.com - Investing.com Canada
Estrella activates second site for EB103 lymphoma trial - Investing.com
Estrella Immunopharma Inc (ESLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Estrella Immunopharma Inc (ESLA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Estrella Immunopharma Inc (ESLA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Estrella Immunopharma Inc (ESLA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Estrella Immunopharma Inc (ESLA) Balance Sheet - TradingKey
Estrella Immunopharma Inc (ESLA) Cash Flow - TradingKey
Estrella Immunopharma Inc (ESLA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ESLA|Estrella Immunopharma Inc|Price:0.750|Chg%:-0.030 - TradingKey
TradingKey - TradingKey
Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Estrella Immunopharma Inc (ESLA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ESLA|Estrella Immunopharma Inc|Price:0.780| - TradingKey
Estrella Immunopharma Inc (ESLA) Institutional Confidence - TradingKey
Estrella doses first patient in EB103 trial expansion phase - Investing.com
Estrella doses first patient in EB103 trial expansion phase By Investing.com - Investing.com Canada
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma - Yahoo Finance
Price to sales forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Enterprise value to EBITDA forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Enterprise value to EBIT forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Estrella Immunopharma, Inc. (ESLA) stock price, news, quote and history - Yahoo Finance UK
Estrella Immunopharma Inc. (ESLA) Q2 2026 Earnings: Wider-than-Expected Loss Despite Double-Digit Stock Rally - vinanet.vn
Enterprise value to revenue forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Estrella Immunopharma Warrants (ESLAW) Slide 7.5% as Support and Resistance Converge at $0.08Ichimoku Kumo Twist - vinanet.vn
Price to earnings forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
ESLA Navigates Biotech Headwinds: Estrella Immunopharma Tests Support at $0.93Volume Dry Up - dars.gov.et
Enterprise value to revenue forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Number of shareholders of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Price to sales forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Estrella Immunopharma Warrant (ESLAW) Holds Steady at $0.10 Amid Low VolatilityCalendar Spread Trade - dars.gov.et
Investigation launched into Estrella Immunophar... - Pluang
AGIG: Abbott Cooper PLLC Announces Investigation on Behalf of Abundia Global Impact Group, Inc. (Formerly Houston American Energy Corp.) Stockholders - GlobeNewswire Inc.
ESLA: Abbott Cooper PLLC Announces Investigation on Behalf of Estrella Immunopharma, Inc. Stockholders - GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
ESLA Q2 2026 Earnings: Wider-than-Expected Loss Triggers Stock DeclineEarnings Cycle Report - dars.gov.et
Tranche Update on Estrella Immunopharma, Inc.'s Equity Buyback Plan announced on January 30, 2024. - marketscreener.com
Estrella Immunopharma, Inc. (ESLA) 8-K Filing: Shareholder Vote Results & Company Details – June 2026 - Minichart
Estrella Immunopharma Shareholders Ratify 2026 Auditor Appointment - TipRanks
Estrella Immunopharma (ESLA) investors back 2026 auditor at virtual annual meeting - Stock Titan
Enterprise value to EBITDA forward of Estrella Immunopharma, Inc. – BOATS:ESLAW - TradingView
Price to earnings forward of Estrella Immunopharma, Inc. – BOATS:ESLAW - TradingView
8.37%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):